Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark forays into...

    Glenmark forays into branded dermatology segment in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-12-26T09:45:53+05:30  |  Updated On 26 Dec 2018 9:45 AM IST
    Glenmark forays into branded dermatology segment in US

    Glenmark is already present in generic dermatology market in the US.


    New Delhi: Glenmark Pharmaceuticals recently announced its foray into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialised by Glenmark Therapeutics Inc USA, Glenmark Pharmaceuticals said in a regulatory filing.


    "This represents an important step in the company's long-term strategy to build a robust branded business in the US, alongside the company's existing and successful generics business," the company added.


    Glenmark is already present in generic dermatology market in the US.


    Read Also: Glenmark Pharma gets USFDA nod for Fluocinolone Acetonide Oil


    Glenmark Therapeutics recently acquired the rights to seven branded dermatology products from Exeltis USA, Inc. The cumulative sales of the seven acquired brands were USD 9 million.


    "All the acquired products are currently approved and marketed in the US, giving Glenmark Therapeutics an immediate entry into the topical branded products segment. In addition, Glenmark Therapeutics intends to launch other branded dermatology products over the next 12 months," Glenmark said.


    "We see strong growth potential in the branded segment, particularly with the kind of products we have acquired and the products we have in our own pipeline in the areas of dermatology and respiratory. With our strategic focus on moving up the value chain, we remain optimistic that these franchises will catalyse the growth trajectory of our US business," said Robert Matsuk, President - North America and Global API, Glenmark Pharmaceuticals.


    Quoting IQVIA sales data for the 12-month period ending October 2018, Glenmark said the topical branded dermatology products market in the US is estimated to be valued at USD 1.9 billion and has been growing at a CAGR of 6.6 per cent over the last five years.


    Also Read: Glenmark pharma gets ANDA approval for Hydrocortisone Valerate Ointment USP, 0 2 pc

    BSECAGRDermatologyGlenmarkGlenmark PharmaGlenmark PharmaceuticalsGlenmark TherapeuticsRobert MatsukU SUnited States
    Source : With input

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok